Cancerdrugdevelopment_3dConsiderable resources are expended for the prevention and treatment of cancer. In fact, it’s the second most common cause of death in the United States, and accounts for $216.6 billion in costs annually.

However, most drugs are prescribed based on histology and not molecular profile. As a result, it is estimated only 25% of patients with any given histologically defined cancer will benefit from any given drug.

With the advent of new technologies and availability of information about the human genetic map and drug targets, there is increasing interest in the use of pharmacogenomic, proteomic and metabalomic information to identify biomarkers for cancer subtype diagnosis, guide drug selection, target therapy and evaluate drug effects on targets.

Molecular-based, personalized cancer therapy enables treatment decisions based on tumor molecular profile rather than traditional histology, resulting in more accurate diagnosis, prognosis and reduced toxicity, leading to improved clinical outcomes such as treatment response and survival.

Download this eBook to learn:

  • The history of cancer diagnosis and treatment
  • The use of molecular profiling in drug development
  • An overview of enabling technologies
  • Regulatory considerations
  • The future of molecular profiling in cancer therapies

If you’re interested in more information about cancer drug development using molecular pathology, please click here to watch a recorded webcast and check out our blog for follow-up Q&A posts.

Back to Blog